Chemotherapy is an ideal of the treatment of cancer, because in has possibilities of systemic treatment which causes neither organic nor functional injury, but now looking for the development of better drugs which are specifically effective against cancer cells, being less injurious to normal tissue.
In the treatment of uterine cervical carcinoma chemotherapy is also still far from practical use.
Bleomycin (BLM) is a hopeful drug which was discovered by Umezawa et al. in 1962 and introduced by Ichikawa et al. as a chemotherapeutic agent selectively effective for the treatment of uterine cervical carcinoma. Fujiwara et al., using
3H-labeled BLM (copper containing complex), studied the distribution of BLM by injecting to the mouse bearing experimentally induced uterine cervical carcinoma.
This paper discribes the fundamental studies both on incluing uterine cervical carcinoma in ICR mice by application of 20-methylcholanthrene and on observing incorporation of
14C-labeled BLM-A
2, which is higher in stability of the specific radiactivity than
3H-BLM, into tumors and various organs after intravenous injection by measuring the radioactivity and the antimicrobial activity in them, and then examine the oncotropic characteristic of BLM. Evidence has been presented: A relatively large amount of BLM may be taked up selectively into squamous epithelium by intravenous injection and the percentage of active BLM may remain the highest in the skin, and next in the uterine cervical carcinoma besides the blood.
View full abstract